Treatment (FLD + SLD) + Detection (Xpert + X-ray + Culture) + Drug susceptibility testing
Cost-effectiveness — what published models estimate per unit of health impact
$/DALY
$21
WHO-CHOICE modeled
GiveWell
—
no GiveWell model
CE sources
2
Tier A · 83 studies
Source agreement
—
2 sources
Scope to country:All countries
Cost-effectiveness
Estimates are sourced in their native units and shown for comparison, not as literal costs. Sources use different frameworks — see each card for what it represents and how it was derived.
Modeled benchmarks ($/DALY)Tier A · standardized benchmark
WHO-CHOICE estimates are modeled at 95% population coverage, compared against the null set (no intervention) under generalized cost-effectiveness analysis. View WHO-CHOICE methodology →
Modeled regional estimates — not realized delivery costs.
Published study estimates ($/DALY)Tier B · context only
Tufts GHCEA · 83 studies, varied methods — explore the spread, not a single number.
Health-system
$184
median · n=62
Mixed
$58
median · n=21
Filter the cohort
$133median of 83 studies · IQR $51–$522 · 10 cost-saving
Data completeness: not assessed (no country selected) · Evidence confidence: not assessed (no country selected)
Looking for supply/market data for Treatment (FLD + SLD) + Detection (Xpert + X-ray + Culture) + Drug susceptibility testing? Select a country above, then open its intelligence page.